Cargando…

2257: Vaccine efficacy and immunogenicity of recombinant WAP and CAP-1 proteins in AKR mice

OBJECTIVES/SPECIFIC AIMS: Trichuris trichiura, is a leading cause of chronic colitis worldwide, resulting in growth stunting, anemia, and cognitive deficits, predominately in children. Our long-term goal is to develop a vaccine against T. trichiura. Both T. trichiura and the closely related Trichuri...

Descripción completa

Detalles Bibliográficos
Autores principales: Briggs, Neima, Versteeg, Leroy, Zhan, Bin, Mejia, Rojelio, Keegan, Brian, Beaumier, Coreen, Sastry, Jagannadha, Elena Bottazzi, Maria, Hotez, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804581/
http://dx.doi.org/10.1017/cts.2017.215
_version_ 1783461230215692288
author Briggs, Neima
Versteeg, Leroy
Zhan, Bin
Mejia, Rojelio
Keegan, Brian
Beaumier, Coreen
Sastry, Jagannadha
Elena Bottazzi, Maria
Hotez, Peter
author_facet Briggs, Neima
Versteeg, Leroy
Zhan, Bin
Mejia, Rojelio
Keegan, Brian
Beaumier, Coreen
Sastry, Jagannadha
Elena Bottazzi, Maria
Hotez, Peter
author_sort Briggs, Neima
collection PubMed
description OBJECTIVES/SPECIFIC AIMS: Trichuris trichiura, is a leading cause of chronic colitis worldwide, resulting in growth stunting, anemia, and cognitive deficits, predominately in children. Our long-term goal is to develop a vaccine against T. trichiura. Both T. trichiura and the closely related Trichuris muris release excretory/secretory (ES) macromolecules from the stichosome organ, which facilitates intracellular invasion into the cecum. We exploited the high degree of genetic sequence homology between T. trichiura and T. muris to evaluate T. muris stichosome proteins as vaccine candidates. METHODS/STUDY POPULATION: Through immunological screening of the T. muris stichosome cDNA library and T. muris ES macromolecules generated in culture, we identified, cloned, and expressed several vaccine candidates. In ranking these antigens, we selected the most promising recombinant proteins, WAP and CAP-1, and vaccinated AKR mice to evaluate the immunogenicity and efficacy of our candidate. In addition, we collected 240 serum samples in the T. trichiura endemic region of Honduras to measure the recognition of WAP and CAP-1 in naturally infected human. RESULTS/ANTICIPATED RESULTS: We measured a statistically significant reduction in larval worm burden in WAP and ES vaccinated mice, but not CAP-1, by microscopy and real-time PCR of T. muris DNA. We found a significant relationship between antigen-specific IgG1:IgG2a ratio in the mouse serum and degree of protection. Mouse splenocytes, vaccine-sensitized draining lymph nodes, and mesenteric lymph nodes were antigen-stimulated and their secreted Th1, Th2, and Th17 cytokines were measured by Luminex(®). Stimulated mouse lymphoid cells were further analysed for T helper, T cytotoxic, and central/effector memory T cells by Flow Cytometry. Human IgG1, IgG2, and IgE antibody titers against WAP and CAP-1 were measured by ELISA. DISCUSSION/SIGNIFICANCE OF IMPACT: In our study, we describe the T cell dependent mechanism of humoral immunity of 2 promising ES-derived vaccines recombinant proteins, WAP and CAP-1. We evaluated the immune response, indicating a driving a Th2-induced humoral response necessary for protection. We further predict protection and allergenicity of WAP in humans using serum from a cohort in an T. trichiura endemic region.
format Online
Article
Text
id pubmed-6804581
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-68045812019-10-28 2257: Vaccine efficacy and immunogenicity of recombinant WAP and CAP-1 proteins in AKR mice Briggs, Neima Versteeg, Leroy Zhan, Bin Mejia, Rojelio Keegan, Brian Beaumier, Coreen Sastry, Jagannadha Elena Bottazzi, Maria Hotez, Peter J Clin Transl Sci Mechanistic Basic to Clinical OBJECTIVES/SPECIFIC AIMS: Trichuris trichiura, is a leading cause of chronic colitis worldwide, resulting in growth stunting, anemia, and cognitive deficits, predominately in children. Our long-term goal is to develop a vaccine against T. trichiura. Both T. trichiura and the closely related Trichuris muris release excretory/secretory (ES) macromolecules from the stichosome organ, which facilitates intracellular invasion into the cecum. We exploited the high degree of genetic sequence homology between T. trichiura and T. muris to evaluate T. muris stichosome proteins as vaccine candidates. METHODS/STUDY POPULATION: Through immunological screening of the T. muris stichosome cDNA library and T. muris ES macromolecules generated in culture, we identified, cloned, and expressed several vaccine candidates. In ranking these antigens, we selected the most promising recombinant proteins, WAP and CAP-1, and vaccinated AKR mice to evaluate the immunogenicity and efficacy of our candidate. In addition, we collected 240 serum samples in the T. trichiura endemic region of Honduras to measure the recognition of WAP and CAP-1 in naturally infected human. RESULTS/ANTICIPATED RESULTS: We measured a statistically significant reduction in larval worm burden in WAP and ES vaccinated mice, but not CAP-1, by microscopy and real-time PCR of T. muris DNA. We found a significant relationship between antigen-specific IgG1:IgG2a ratio in the mouse serum and degree of protection. Mouse splenocytes, vaccine-sensitized draining lymph nodes, and mesenteric lymph nodes were antigen-stimulated and their secreted Th1, Th2, and Th17 cytokines were measured by Luminex(®). Stimulated mouse lymphoid cells were further analysed for T helper, T cytotoxic, and central/effector memory T cells by Flow Cytometry. Human IgG1, IgG2, and IgE antibody titers against WAP and CAP-1 were measured by ELISA. DISCUSSION/SIGNIFICANCE OF IMPACT: In our study, we describe the T cell dependent mechanism of humoral immunity of 2 promising ES-derived vaccines recombinant proteins, WAP and CAP-1. We evaluated the immune response, indicating a driving a Th2-induced humoral response necessary for protection. We further predict protection and allergenicity of WAP in humans using serum from a cohort in an T. trichiura endemic region. Cambridge University Press 2018-05-10 /pmc/articles/PMC6804581/ http://dx.doi.org/10.1017/cts.2017.215 Text en © The Association for Clinical and Translational Science 2018 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Mechanistic Basic to Clinical
Briggs, Neima
Versteeg, Leroy
Zhan, Bin
Mejia, Rojelio
Keegan, Brian
Beaumier, Coreen
Sastry, Jagannadha
Elena Bottazzi, Maria
Hotez, Peter
2257: Vaccine efficacy and immunogenicity of recombinant WAP and CAP-1 proteins in AKR mice
title 2257: Vaccine efficacy and immunogenicity of recombinant WAP and CAP-1 proteins in AKR mice
title_full 2257: Vaccine efficacy and immunogenicity of recombinant WAP and CAP-1 proteins in AKR mice
title_fullStr 2257: Vaccine efficacy and immunogenicity of recombinant WAP and CAP-1 proteins in AKR mice
title_full_unstemmed 2257: Vaccine efficacy and immunogenicity of recombinant WAP and CAP-1 proteins in AKR mice
title_short 2257: Vaccine efficacy and immunogenicity of recombinant WAP and CAP-1 proteins in AKR mice
title_sort 2257: vaccine efficacy and immunogenicity of recombinant wap and cap-1 proteins in akr mice
topic Mechanistic Basic to Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804581/
http://dx.doi.org/10.1017/cts.2017.215
work_keys_str_mv AT briggsneima 2257vaccineefficacyandimmunogenicityofrecombinantwapandcap1proteinsinakrmice
AT versteegleroy 2257vaccineefficacyandimmunogenicityofrecombinantwapandcap1proteinsinakrmice
AT zhanbin 2257vaccineefficacyandimmunogenicityofrecombinantwapandcap1proteinsinakrmice
AT mejiarojelio 2257vaccineefficacyandimmunogenicityofrecombinantwapandcap1proteinsinakrmice
AT keeganbrian 2257vaccineefficacyandimmunogenicityofrecombinantwapandcap1proteinsinakrmice
AT beaumiercoreen 2257vaccineefficacyandimmunogenicityofrecombinantwapandcap1proteinsinakrmice
AT sastryjagannadha 2257vaccineefficacyandimmunogenicityofrecombinantwapandcap1proteinsinakrmice
AT elenabottazzimaria 2257vaccineefficacyandimmunogenicityofrecombinantwapandcap1proteinsinakrmice
AT hotezpeter 2257vaccineefficacyandimmunogenicityofrecombinantwapandcap1proteinsinakrmice